143 related articles for article (PubMed ID: 26123203)
1. Functional POR A503V is associated with the risk of bladder cancer in a Chinese population.
Xiao X; Ma G; Li S; Wang M; Liu N; Ma L; Zhang Z; Chu H; Zhang Z; Wang SL
Sci Rep; 2015 Jun; 5():11751. PubMed ID: 26123203
[TBL] [Abstract][Full Text] [Related]
2. Study on bladder cancer susceptibility and genetic polymorphisms of XPC, XPG, and CYP in smokers and non-smokers.
Wen H; Feng CC; Fang ZJ; Xia GW; Jiang HW; Xu G; Huang XD; Ding Q
Actas Urol Esp; 2013 May; 37(5):259-65. PubMed ID: 23246108
[TBL] [Abstract][Full Text] [Related]
3. Effects of TSP-1-696 C/T polymorphism on bladder cancer susceptibility and clinicopathologic features.
Gu J; Tao J; Yang X; Li P; Yang X; Qin C; Cao Q; Cai H; Zhang Z; Wang M; Gu M; Lu Q; Yin C
Cancer Genet; 2014 Jun; 207(6):247-52. PubMed ID: 25150583
[TBL] [Abstract][Full Text] [Related]
4. c.29C>T polymorphism in the transforming growth factor-β1 (TGFB1) gene correlates with increased risk of urinary bladder cancer.
Gautam KA; Pooja S; Sankhwar SN; Sankhwar PL; Goel A; Rajender S
Cytokine; 2015 Oct; 75(2):344-8. PubMed ID: 26048435
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer.
Wang M; Wang M; Cheng G; Zhang Z; Fu G; Zhang Z
Mutat Res; 2009 Feb; 661(1-2):85-92. PubMed ID: 19070628
[TBL] [Abstract][Full Text] [Related]
6. A Novel PCR-RFLP Method for Detection of POR*28 Polymorphism and its Genotype/Allele Frequencies in a Turkish Population.
Ozdemir F; Oz MD; Suzen HS
Curr Drug Metab; 2019; 20(10):845-851. PubMed ID: 31518218
[TBL] [Abstract][Full Text] [Related]
7. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand and death receptor genes contribute to susceptibility to bladder cancer.
Timirci-Kahraman O; Ozkan NE; Turan S; Farooqi AA; Verim L; Ozturk T; Inal-Gultekin G; Isbir T; Ozturk O; Yaylim I
Genet Test Mol Biomarkers; 2015 Jun; 19(6):309-15. PubMed ID: 25955868
[TBL] [Abstract][Full Text] [Related]
9. P450 oxidoreductase deficiency: a disorder of steroidogenesis with multiple clinical manifestations.
Miller WL
Sci Signal; 2012 Oct; 5(247):pt11. PubMed ID: 23092891
[TBL] [Abstract][Full Text] [Related]
10. Association of bladder cancer risk with an NAD(P)H:quinone oxidoreductase polymorphism in an ethnic Kashmiri population.
Pandith AA; Khan NP; Shah ZA; Shah AM; Wani SM; Siddiqi MA
Biochem Genet; 2011 Aug; 49(7-8):417-26. PubMed ID: 21253823
[TBL] [Abstract][Full Text] [Related]
11. Do DNA repair genes OGG1, XRCC3 and XRCC7 have an impact on susceptibility to bladder cancer in the North Indian population?
Gangwar R; Ahirwar D; Mandhani A; Mittal RD
Mutat Res; 2009; 680(1-2):56-63. PubMed ID: 19815090
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer.
Ahirwar D; Mandhani A; Mittal RD
Arch Med Res; 2009 Feb; 40(2):97-102. PubMed ID: 19237018
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants in RUNX3 and risk of bladder cancer: a haplotype-based analysis.
Zhang Z; Wang S; Wang M; Tong N; Fu G; Zhang Z
Carcinogenesis; 2008 Oct; 29(10):1973-8. PubMed ID: 18684727
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation in human P450 oxidoreductase.
Miller WL; Huang N; Agrawal V; Giacomini KM
Mol Cell Endocrinol; 2009 Mar; 300(1-2):180-4. PubMed ID: 18930113
[TBL] [Abstract][Full Text] [Related]
15. Genetic variants of XRCC1, APE1, and ADPRT genes and risk of bladder cancer.
Wang M; Qin C; Zhu J; Yuan L; Fu G; Zhang Z; Yin C
DNA Cell Biol; 2010 Jun; 29(6):303-11. PubMed ID: 20218899
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study.
Lin J; Spitz MR; Wang Y; Schabath MB; Gorlov IP; Hernandez LM; Pillow PC; Grossman HB; Wu X
Carcinogenesis; 2004 Sep; 25(9):1639-47. PubMed ID: 15117811
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms of cytochrome P450 CYP1A1 (*2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer: a study from North India.
Srivastava DS; Mandhani A; Mittal RD
Arch Toxicol; 2008 Sep; 82(9):633-9. PubMed ID: 18200441
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the H19 gene and the risk of bladder cancer.
Verhaegh GW; Verkleij L; Vermeulen SH; den Heijer M; Witjes JA; Kiemeney LA
Eur Urol; 2008 Nov; 54(5):1118-26. PubMed ID: 18262338
[TBL] [Abstract][Full Text] [Related]
19. Genetic variants of the cytochrome P450 and glutathione S-transferase associated with risk of bladder cancer in a south-eastern Chinese population.
Shao J; Gu M; Zhang Z; Xu Z; Hu Q; Qian L
Int J Urol; 2008 Mar; 15(3):216-21. PubMed ID: 18304215
[TBL] [Abstract][Full Text] [Related]
20. Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population.
Li H; Li S; Wang Q; Jia C
Hum Genet; 2016 Dec; 135(12):1389-1397. PubMed ID: 27660057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
